Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration

Retina

Volumn 22, Issue 2, 2002, Pages 143-152

  Martin, Daniel F ^b   Klein, Michael ^c   Haller, Julia ^d   Adamis, Anthony ^e   Gragoudas, Evangelos ^e   Miller, Joan ^e   Blumenkrantz, Mark ^f   Goldberg, Morton ^g   Yannuzzi, Lawrence ^h   Henninger, Dwight ⁱ   Wiegand, Laurie B ⁱ   Chen, Long Shiuh ⁱ   Drolet, Daniel W ⁱ   Gill, Stanley C ⁱ   Bill, Jerry ⁱ   Tomkinson, Blake ⁱ   Bendele, R A ⁱ   O'Shaughnessy, Denis ^j   Guyer, David R ^a,j   Patel, Samir ^j  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CASEY EYE INSTITUTE   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h Howard Hughes Medical Institute   (United States)

ⁱ GILEAD SCIENCES   (United States)

^j OSI PHARMACEUTICALS INC   (United States)

more..

Author keywords

Age related macular degeneration; Angiogenesis; Pharmacologic intervention; Vascular endothelial growth factor

Indexed keywords

APTAMER; PEGAPTANIB; PEGYLATED VASCULOTROPIN ANTIBODY APTAMER; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

ADULT; AGED; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DISEASE; DIABETIC RETINOPATHY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG SAFETY; EARLY DIAGNOSIS; EYE INFLAMMATION; EYE PAIN; FATIGUE; FEMALE; HUMAN; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; RAT; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; SCOTOMA; STIMULUS RESPONSE; SUBRETINAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;

AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL AVAILABILITY; CAPILLARY PERMEABILITY; CHOROIDAL NEOVASCULARIZATION; CORNEAL NEOVASCULARIZATION; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL GROWTH FACTORS; EXUDATES AND TRANSUDATES; FEMALE; FLUORESCEIN ANGIOGRAPHY; GUINEA PIGS; HALF-LIFE; HUMANS; INFANT, NEWBORN; INJECTIONS; LYMPHOKINES; MACULAR DEGENERATION; MALE; MICE; MICE, NUDE; MIDDLE AGED; OLIGONUCLEOTIDES; RABBITS; RATS; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; SKIN; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; VITREOUS BODY;

EID: 0036959644     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200204000-00002     Document Type: Article

References (25)

1. Ghafour IM, Allan D, Fould WS. Common causes of blindness and visual handicap in the west of Scotland. Br J Ophthalmol 1983;67:209-213.
2. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987;1:330-341.
3. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Results of a randomized trial. Arch Ophthalmol 1990;108:816-824.
4. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular retinopathy after five years. Results from randomized clinical trials. Arch Ophthalmol 1991;109:1109-1114.
5. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991;109:1219-1230.
6. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol 1999;117:1329-1345.
7. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992;13:18-31.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
9. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-985.
10. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-442.
11. Carmeliet P, Ferreira V, Breir G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993;362:841-844.
13. Huang J, Moore J, Soffer S, et al. Highly specific antiangiogenic therapy is effective in suppressing growth of experimental Wilms tumors. J Pediatr Surg 2001;36:357-361.
14. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18-22.
15. Adamis AP, Shima DT, Tolentino M, et al. Inhibition of VEGF prevents retinal ischemia-associated iris neovascularization in a primate. Arch Ophthalmol 1996;114:66-71.
16. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:23:10457-10461.
17. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994;35:101-111.
18. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37: 855-868.
19. Adamis AP, Miller J, Bernal M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-450.
20. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
21. Afshari MA, Krzystolik MG, Adamis AP, et al. Therapeutic and prophylactic effects of a recombinant human binding fragment of a monoclonal antibody directed to vascular endothelial growth factor (rhuFab VEGF) in a monkey model of laser-induced choroidal neovascularization [ARVO abstract]. Invest Ophthalmol Vis Sci 2001;42:S933.
22. Quam T, Xu Q, Joussen AM, et al. VEGF-initiated blood-retinal breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2412.
23. Tucker CE, Chen L-S, Judkins MB, Farmer JA, Gill SC, Drolet DW. Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys. J Chromatogr Biomed Appl 1999;732:203-212.
24. Drolet DW, Nelson J, Tucker CE, et al. Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 2000;17:1503-1510.
25. The Radiation Therapy for Age-related Macular Degeneration (RAD) Study Group. A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD Study). Ophthalmology 1999;106:2239-2247.